New Brunswick, NJ - The Rutgers University iJOBS Program, funded by the National Institutes of Health, prepares biomedical scientists for a range of careers in five professional tracks: i) science and health policy, ii) business management, iii) intellectual property management, iv) clinical and regulatory sciences, and v) health and science data analysis.
Washington D.C. - The Federation of American Societies for Experimental Biology (FASEB) has calculated New Jersey Federal research funding for fiscal year 2014. They have developed an interactive map for New Jersey and its individual congressional districts.
Bethesda, MD – The Federation of American Societies for Experimental Biology (FASEB) has released new interactive factsheets summarizing federal science funding in states and U.S. congressional districts. This is the only resource to feature up-to-date information about federal science funding at the district level and make it accessible to the general public.
New Brunswick, NJ - A new study by researchers from Rowan University School of Medicine in Stratford and Rutgers New Jersey Medical School in Newark recently showed Bisphenol-A (BPA) is linked to autism. RowanSOM's Dr. T. Peter Stein, the study's lead author, said the study -- conducted on both children with autism and children without -- shows that BPA is processed differently in children on the autism spectrum.
New Brunswick, NJ, December 9, 2014 ― A Rutgers researcher has received a grant of nearly $640,000 from the National Institutes of Health to develop a rapid test to diagnose Ebola as well as other viruses that can cause symptoms similar to Ebola.
David Alland, a professor of medicine and associate dean for clinical research at Rutgers New Jersey Medical School — and the principal investigator for the project — says health workers would be able to take the test to small villages and other remote locations where the spread of Ebola has been especially rampant and diagnose patients where they live.
The test could be used wherever electricity is available, including power from car batteries, according to Alland. “That means diagnosis would take significantly shorter than the time it takes to get a test result now from a medical lab,” he says.
Alland, working with the California biotechnology company Cepheid, hopes to develop the test within the next 15 months — using genetic material from Ebola and other viruses that cannot cause or spread disease. Work in Alland’s laboratory will not involve the use of live virus.
Alland and Cepheid previously used technology similar to the planned Ebola test to develop a rapid test for tuberculosis (TB) that is now widely used in impoverished areas of the world.
As they produce their test for the Ebola virus, Alland and Cepheid also plan to create rapid diagnostic tests for other viral illnesses, including chikungunya — a painful mosquito-borne disease that, according to the CDC, sickened more than 140 people in New Jersey this year after those people had visited tropical regions in the Caribbean and Asia and islands in the Pacific.
For the full Rutgers story, click here.
Do not miss a single innovative moment and sign up for our newsletter!